Clinical Trial Update: LEADER (LEvocetirizine And DEsloratadine in Allergic Rhinitis) [Phase 4]

View source ↗

Summary

Phase 4 LEADER trial evaluating levocetirizine and desloratadine for allergic rhinitis has completed, sponsored by UCB Pharma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Allergic Rhinitis

Drugs mentioned

• Clarinex (desloratadine)
• XYZAL (LEVOCETIRIZINE DIHYDROCHLORIDE)

Snippet

Sponsor: UCB Pharma | Conditions: Rhinitis, Allergic, Perennial | Phase 4 | Status: COMPLETED